

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	E1A binding protein p300 (EP300; p300)	<p>Studies in mice suggest inhibiting p300 could help treat cancer by promoting antitumor immunity. In an immunocompetent mouse model of cancer, animals with T_{reg}-specific p300 knockout had lower tumor growth and tumor T_{reg} infiltration and greater CD8⁺ T cell infiltration than mice without p300 knockout. In two immunocompetent mouse models of cancer, a small molecule p300 inhibitor increased antitumor immune responses and decreased tumor growth compared with vehicle. Next steps include testing more potent inhibitors of p300 with better pharmacokinetics.</p> <p>Acylin Therapeutics Inc. has p300 inhibitors in preclinical development.</p> <p>SciBX 6(37); doi:10.1038/scibx.2013.1022 Published online Sept. 26, 2013</p>	Patent application filed; available for licensing	<p>Liu, Y. <i>et al. Nat. Med.</i>; published online Aug. 18, 2013; doi:10.1038/nm.3286</p> <p>Contact: Wayne W. Hancock, The Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa. e-mail: whancock@mail.med.upenn.edu</p>